BS_T1DVKKJB
EPN · Supratentorial EPN
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- EPN
- cancer_type_detailed
- —
- subtype
- Supratentorial EPN
- cancer_type
- EPN
- subtype
- Supratentorial EPN
- overall_survival_months
- 140.88
- os_event
- false
- age_years
- 8.611
- fusion
- ZFTA_RELA
- e1_e2
- E1
- umap1_2d
- -2.383400359
- umap2_2d
- 0.787989817
- umap1_3d
- 0.829008063
- umap2_3d
- 3.011543729
- umap3_3d
- -2.719230924
- dataset
- EPN-CBTN
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TNFA_SIGNALING_VIA_NFKB+0.490
- INFLAMMATORY_RESPONSE+0.410
- ANGIOGENESIS+0.390
- ALLOGRAFT_REJECTION+0.360
- INTERFERON_GAMMA_RESPONSE+0.360
- PANCREAS_BETA_CELLS+0.350
- HYPOXIA+0.340
- IL6_JAK_STAT3_SIGNALING+0.320
- INTERFERON_ALPHA_RESPONSE+0.270
- UV_RESPONSE_UP+0.240
Top 10 suppressed
- MYC_TARGETS_V1-0.400
- OXIDATIVE_PHOSPHORYLATION-0.370
- PROTEIN_SECRETION-0.300
- TGF_BETA_SIGNALING-0.230
- MYC_TARGETS_V2-0.170
- HEME_METABOLISM-0.160
- MITOTIC_SPINDLE-0.120
- DNA_REPAIR-0.100
- FATTY_ACID_METABOLISM-0.100
- PEROXISOME-0.090
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_T1DVKKJB | Supratentorial Ependymoma | — | 0.933 |
| 2 | X41226e40.d143.43b1.ac92.023809990077 | — | cohortA1 | 0.866 |
| 3 | BS_PJPGVD62 | Ependymoma NOS | — | 0.851 |
| 4 | SJEPD001506_D1.RNA-Seq | EPN | Posterior Fossa EPN | 0.847 |
| 5 | BS_N4B1SZZH | Med | Medulloblastoma | 0.845 |
| 6 | SRR2778056 | — | — | 0.832 |
| 7 | R107 | — | — | 0.829 |
| 8 | BS_PJPGVD62 | EPN | EPN Tumor | 0.827 |
| 9 | MNG1293 | — | — | 0.827 |
| 10 | SJEPD038_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.826 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TNFA_SIGNALING_VIA_NFKB | 0.490 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.410 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.390 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.360 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.360 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.350 | Cobimetinib | — uncovered |
| HYPOXIA | 0.340 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.320 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.270 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.240 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.240 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.210 | Temsirolimus | — uncovered |
| P53_PATHWAY | 0.210 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.190 | Inavolisib | — uncovered |
| APOPTOSIS | 0.190 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.190 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.170 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.150 | Inavolisib | — uncovered |
| COMPLEMENT | 0.140 | Inavolisib | — uncovered |